CALC

Company Overview — What Does CalciMedica, Inc. Do?

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC, Graybug Vision, Inc. in 2016 and changed its name to CalciMedica, Inc. in 2023. CalciMedica, Inc. was incorporated in 2011 and is based in Redwood City, California. CalciMedica, Inc. (CALC) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Frédéric Guerard and employs approximately 30 people. With a market capitalization of $9M, CALC is one of the notable companies in the Healthcare sector.

CalciMedica, Inc. (CALC) Stock Rating — Avoid (April 2026)

As of April 2026, CalciMedica, Inc. receives a Avoid rating with a composite score of 20.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CALC ranks #4,349 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CalciMedica, Inc. ranks #799 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CALC Stock Price and 52-Week Range

CalciMedica, Inc. (CALC) currently trades at $0.64. The stock lost $0.01 (2.2%) in the most recent trading session. The 52-week high for CALC is $7.20, which means the stock is currently trading -91.2% from its annual peak. The 52-week low is $0.50, putting the stock 26.4% above its annual trough. Recent trading volume was 170K shares, suggesting relatively thin trading activity.

Is CALC Overvalued or Undervalued? — Valuation Analysis

CalciMedica, Inc. (CALC) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth.

At current multiples, CalciMedica, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CalciMedica, Inc. Profitability — ROE, Margins, and Quality Score

CalciMedica, Inc. (CALC) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -179.7% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CALC Debt, Balance Sheet, and Financial Health

Balance sheet data for CALC is evaluated through our stability factor. The current ratio is 3.58x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $5M.

CALC has a beta of 0.28, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for CalciMedica, Inc. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CalciMedica, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, CalciMedica, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.97. Net income for the quarter was $-24M. Operating income came in at $-24M.

In FY 2025, CalciMedica, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.97. Net income for the quarter was $-30M. Operating income came in at $-23M.

In Q3 2025, CalciMedica, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.52. Net income for the quarter was $-8M. Operating income came in at $-6M.

In Q2 2025, CalciMedica, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.40. Net income for the quarter was $-6M. Operating income came in at $-7M.

Over the past 8 quarters, CalciMedica, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing CALC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CALC Dividend Yield and Income Analysis

CalciMedica, Inc. (CALC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CALC Momentum and Technical Analysis Profile

CalciMedica, Inc. (CALC) has a momentum factor score of 9/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

CALC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CalciMedica, Inc. (CALC) ranks #799 out of 838 stocks based on the Blank Capital composite score. This places CALC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CALC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CALC vs S&P 500 (SPY) comparison to assess how CalciMedica, Inc. stacks up against the broader market across all factor dimensions.

CALC Next Earnings Date

No upcoming earnings date has been announced for CalciMedica, Inc. (CALC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CALC? — Investment Thesis Summary

The quantitative profile for CalciMedica, Inc. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Momentum is weak at 9/100, a headwind for near-term performance. High volatility (stability score 31/100) increases portfolio risk.

In summary, CalciMedica, Inc. (CALC) earns a Avoid rating with a composite score of 20.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CALC stock.

Related Resources for CALC Investors

Explore more research and tools: CALC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CALC head-to-head with peers: CALC vs AZN, CALC vs SLGL, CALC vs VMD.